New insights into why some children with rhabdomyosarcoma (RMS) develop aggressive disease despite being classified as non-high-risk have been uncovered. Read more: https://medicalxpress.com/news/2026-08-hidden-aggressive-cells-reveal-childhood.html

Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment outcome in an adolescent with an advanced, treatment-resistant kidney tumor. Read more: https://medicalxpress.com/news/2026-08-personalized-cell-therapy-metastatic-kidney.html

A new, high-quality study reveals that the cardioprotective drug dexrazoxane significantly reduces the heart damage caused by chemotherapy received by pediatric cancer patients 15 years or more after treatment ends. Read more: https://news.ufl.edu/2026/08/chemotherapy-heart-protecting-drug/

Scientists found that the protein promotes survival of KMT2A-rearranged leukemia, presenting a previously unappreciated vulnerability. Read more: https://www.stjude.org/media-resources/news-releases/2026-medicine-science-news/mbnl1-identified-as-potential-cancer-drug-target-for-type-of-childhood-leukemia.html

In a study, Black and Hispanic parents were largely willing to enroll children in oncology trials, while clinicians cited hardship and gatekeeping as barriers. Read more: https://www.cancernetwork.com/view/what-limits-pediatric-oncology-trial-access-for-marginalized-families-

Researchers at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center are zeroing in on less toxic and more targeted strategies to combat Ewing sarcoma, an aggressive and rare pediatric cancer that develops in the bones and soft tissues. Read more: https://medicalxpress.com/news/2026-08-biochemists-strategy-combat-pediatric-bone.html

Few young adults receive palliative care (PC) as part of treatment for stage 4 solid tumors or poor-prognosis high-grade brain tumors, according to a research letter published online July 23 in JAMA Network Open. Read more: https://www.oncologynurseadvisor.com/news/few-young-adults-receive-palliative-care-as-part-of-advanced-cancer-treatment/

A new scientific breakthrough may soon mean hope for children and families facing one of pediatric cancer’s deadliest foes. Instead of targeting viruses or bacteria, this new mRNA vaccine is setting its sights on an aggressive childhood tumor: neuroblastoma. Read more: https://www.futura-sciences.com/en/a-childhood-cancer-faces-a-new-enemy-this-mrna-vaccine-isnt-for-viruses_36759/

Adult childhood cancer survivors (CCS) of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL) frequently report mental distress, fatigue and executive function (EF) impairment, according to a study published online in Current Oncology. Read more: https://medicalxpress.com/news/2026-07-mental-distress-fatigue-common-childhood.html

Nearly half of childhood tumors treated with common types of chemotherapy showed detectable DNA changes linked to treatment within 18 months, according to a new international study led by The Hospital for Sick Children (SickKids). Researchers say these changes could eventually help clinicians spot treatment resistance earlier, before cancer returns or spreads, opening the door to a more precise use of chemotherapy. Read more: https://www.news-medical.net/news/20260723/Chemot